# Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

> **NCT04872790** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Mixed Phenotype Acute Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Mixed Phenotype Acute Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Methotrexate
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Venetoclax
- **BIOLOGICAL:** Blinatumomab
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04872790
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-02
- **Primary completion:** 2027-12-02
- **Final completion:** 2027-12-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04872790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04872790, "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04872790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*